Frailty screening and glycaemic control in preterm neonates: A cross-sectional survey
Published
February 15, 2024
Paper ID
PAP-000051
Status
Published
DOI
10.65712/tmj.test000309
Advance Services
Abstract
Background: The cost of glycaemic control to health systems is substantial. Methods: We conducted a cross-sectional survey across 10 centres between 2015 and 2023. Results: Serious adverse events were rare and similar between groups. Effects were consistent across prespecified subgroups. Conclusion: Residual confounding cannot be excluded.
Introduction
Practice around frailty screening varies widely between centres. Guidelines make only a weak recommendation on frailty screening. Earlier studies of frailty screening were small or single-centre.
The cost of glycaemic control to health systems is substantial. Earlier studies of frailty screening were small or single-centre. Guidelines make only a weak recommendation on frailty screening.
Earlier studies of frailty screening were small or single-centre. Guidelines make only a weak recommendation on frailty screening. glycaemic control remains a leading cause of avoidable harm among preterm neonates.
Materials and Methods
We conducted a cross-sectional survey across 2 centres between 2020 and 2021. We conducted a cross-sectional survey across 12 centres between 2018 and 2021. We conducted a cross-sectional survey across 6 centres between 2016 and 2024. The primary outcome was glycaemic control, assessed blind to allocation.
We conducted a cross-sectional survey across 7 centres between 2018 and 2025. Missing data were handled with multiple imputation.
Results
Effects were consistent across prespecified subgroups. 4325 participants were included (median age 37 years). glycaemic control occurred in 9% of the intervention group versus 37% of controls.
| Group | n | Events | Rate % |
|---|---|---|---|
| Intervention | 291 | 67 | 27.9 |
| Male | 317 | 11 | 9.0 |
| Control | 464 | 38 | 3.9 |
Values are n (%) unless stated otherwise.

Shown for preterm neonates; error bars are 95% confidence intervals.

Shown for preterm neonates; error bars are 95% confidence intervals.
The adjusted odds ratio was 0.86 (95% CI 0.24 to 0.99). glycaemic control occurred in 5% of the intervention group versus 33% of controls. Serious adverse events were rare and similar between groups.
The adjusted odds ratio was 0.73 (95% CI 0.47 to 0.94). glycaemic control occurred in 15% of the intervention group versus 36% of controls.
Discussion
Residual confounding cannot be excluded. These findings suggest that frailty screening is associated with better glycaemic control in preterm neonates.
Strengths include the sample size and blinded outcome assessment. Future work should test frailty screening in a pragmatic multicentre trial.
Residual confounding cannot be excluded. Future work should test frailty screening in a pragmatic multicentre trial.
Conclusions
Frailty screening is a reasonable option for preterm neonates to improve glycaemic control.
References
1. Kaur A, Kaur L, et al. Telemedicine follow-up and glycaemic control. Eur Heart J. 2012;168(6):576-1509.
2. Dubois N, Ibrahim C, et al. An enhanced recovery pathway and length of stay. BMJ. 2012;293(11):729-1329.
3. Moreau L, Schmidt T, et al. Low-dose aspirin and post-operative delirium. BMJ. 2017;175(5):412-1213.
4. Kowalski K, Costa A, et al. Point-of-care ultrasound and emergency department revisits. JAMA. 2023;164(7):450-1002.
5. Osei I, Kowalski F, et al. An antibiotic stewardship programme and emergency department revisits. Lancet. 2017;363(9):712-1378.
6. Moreau I, Patel W, et al. A sepsis alert system and falls. BMC Med. 2015;300(8):561-1646.
7. Mensah M, Herrera W, et al. High-flow nasal oxygen and medication adherence. BMJ. 2018;376(9):763-1740.
8. Costa I, Mueller A, et al. Tranexamic acid and length of stay. Diabetes Care. 2012;150(8):646-1429.
9. Rahman A, Kaur L, et al. Delayed cord clamping and chronic pain scores. Eur Heart J. 2011;224(8):516-1098.
Appendices
Supplementary tables are available on request.